Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer - Wikidata - wikimedia - TriplyDB

Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer

Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer

http://www.wikidata.org/entity/Q27674784

about

Therapeutic targeting of cancers with loss of PTEN function.Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents In vitro models of cancer stem cells and clinical applications Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular response A Multilayer Network Approach for Guiding Drug Repositioning in Neglected Diseases Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development Genetically engineered mouse models of PI3K signaling in breast cancer.Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment Combination therapy of prostate cancer with HPMA copolymer conjugates containing PI3K/mTOR inhibitor and docetaxel Selective and potent small-molecule inhibitors of PI3Ks.Determination of GDC-0980 (apitolisib), a small molecule dual phosphatidylinositide 3-kinase/mammalian target of rapamycin inhibitor in dog plasma by LC-MS/MS to support a GLP toxicology study.Safety and efficacy of everolimus in adult patients with neuroendocrine tumors.Autophagy Correlates with the Therapeutic Responsiveness of Malignant Pleural Mesothelioma in 3D Models.Mitotic arrest of breast cancer MDA-MB-231 cells by a halogenated thieno[3,2-d]pyrimidine.Antiproliferative activities of halogenated thieno[3,2-d]pyrimidines MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma.N-(2-Hydroxypropyl)methacrylamide Copolymer-Drug Conjugates for Combination Chemotherapy of Acute Myeloid Leukemia Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells.Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR.Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors.Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes.A comprehensive transcriptional portrait of human cancer cell lines.Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors.Phosphoinositide 3-kinase α inhibitors: a patent review.Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment.Targets, structures, and recent approaches in malignant melanoma chemotherapy.Targeting angiogenesis in renal cell carcinoma.Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer Targeting PI3Kδ: emerging therapy for chronic lymphocytic leukemia and beyond.Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review.mTOR Inhibitors at a Glance.A probabilistic method to report predictions from a human liver microsomes stability QSAR model: a practical tool for drug discovery.5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.Phosphoproteomic analysis implicates the mTORC2-FoxO1 axis in VEGF signaling and feedback activation of receptor tyrosine kinases.Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity.

P2860

Q27852764-DB9109F2-CC12-4EA2-977A-F319952A8529 Q27853324-B043B8FD-D80B-46BE-9ECD-45B2E8EA9C3A Q28067417-A2E4185F-F6E4-477A-8A06-AE1BA5CB078B Q28076101-8CA91642-5162-4AC1-A599-E6813FE37E78 Q28384680-67CD999E-0708-4213-B5D4-143814F05864 Q28552140-71C7F8F4-2CA1-4925-BB3F-566E20264D91 Q33776641-E0E7DF3A-381F-444D-9E02-D243570B4832 Q34332175-8C0FB34B-7AF7-424E-959A-E5ADF3098806 Q34508976-C3884845-12C2-4AFF-8B1A-E3B76C55E2A5 Q35164454-63CE57BD-CEA4-4844-8C7E-06B9B070685F Q35190512-D7CCC7A9-E29F-415C-98FB-A70A852BA432 Q35560282-AD5327D2-5067-427B-B930-C35C2B355104 Q35669138-C76464AC-848C-4F5D-92C0-8175F8C38EDB Q35748646-C8037D76-BC7B-4E93-A2D8-95DD5BB1C048 Q36015911-D99AC1FF-6FA6-43C1-AEC5-7D9711AEBD29 Q36047250-21C38E70-1434-4AB5-B161-C6C117A3A8F8 Q36546300-A76D9EB0-98C8-45D2-96B9-DF86DDA46B64 Q36722841-EB2F3B99-1DB6-484E-B0F9-323778CFE05A Q36772192-F3DDA255-0BC7-4309-97F0-7850E46D6B57 Q36806807-B67E7F71-5BEF-4659-B295-166FDD78F6B1 Q37011768-EFF27AD2-162D-482D-B517-4F91E0A45947 Q37350230-1486BFB1-B835-4C65-9F37-75F401A086CD Q37565213-34D5C82C-DA6E-4C80-8653-C04FE6AD1126 Q37584321-320DB62B-4C70-4F23-A76B-B92E019244D4 Q37727180-0F178C17-EC4F-4590-81A4-7D8801E4175A Q37854720-7E97B64E-CE6F-4A2C-98F8-83B0F65B2E80 Q38074121-F0E21B25-2D5E-42B5-B203-50643BB82083 Q38089138-680A3785-F101-4380-9C40-5B9E315F396E Q38106130-B2241FF3-6601-42CD-B0B8-A0180708A5E2 Q38129832-1B2B6301-3B3E-42CE-9601-5640298161B8 Q38132231-8D25C3FB-3D0A-40E0-8823-554E399620F7 Q38311480-E89BBB22-187C-472D-BDFD-1FA710E73225 Q38375141-415CCC1C-8C5E-4742-982B-9AB19B4DA7BE Q38515841-9634A6A1-2363-4BC8-8534-2865A2741B6C Q40760533-FEEEF099-38E9-45A0-9361-99C0BFE5E930 Q41363342-2024AF32-AC7F-431C-9419-8B023844943C Q42632563-0D3D9068-F5C4-441C-BE2D-B0AD0EFC7F43 Q46574147-3B4DD029-5240-42C8-A9D7-9D9C424D0EEC Q47955211-76841011-CA30-4499-AD4C-8D702540FC21 Q48684041-984AC1C5-71C4-49E9-BAD9-2BBF4AE55CF7

P2860

Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer

http://www.wikidata.org/entity/Q27674784

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Discovery of a potent, selecti ...... 0) for the treatment of cancer

@ast

Discovery of a potent, selecti ...... 0) for the treatment of cancer

@en

Discovery of a potent, selecti ...... 0) for the treatment of cancer

@nl

type

label

Discovery of a potent, selecti ...... 0) for the treatment of cancer

@ast

Discovery of a potent, selecti ...... 0) for the treatment of cancer

@en

Discovery of a potent, selecti ...... 0) for the treatment of cancer

@nl

prefLabel

Discovery of a potent, selecti ...... 0) for the treatment of cancer

@ast

Discovery of a potent, selecti ...... 0) for the treatment of cancer

@en

Discovery of a potent, selecti ...... 0) for the treatment of cancer

@nl

P1433

Q27674784-06ED4832-D136-40D0-8A35-825CA4AD797C

P1476

Q27674784-7A3A4539-602D-48BA-9323-E5C9661C7623

P2093

Q27674784-072A13FA-E595-487B-91FC-27AAB5A46331

Q27674784-0D498F18-2A2A-46DB-85E3-B677A7FDBF14

Q27674784-24294B3F-8D84-477A-80E8-0D52386FC301

Q27674784-28E5A5DD-ABDD-42B9-A504-D626611EECF5

Q27674784-2A6B1B81-2476-43CF-A78B-6ED43607D252

Q27674784-3EA312F8-50E9-4D29-B04B-878410412D1B

Q27674784-3F44C7C3-F0AE-42C3-AED9-3C14D503AC5A

Q27674784-415AE756-41FB-4A57-A882-7B3E46216AAF

Q27674784-48158258-5E41-488B-9168-6C72192400D7

Q27674784-4E5573D2-596A-40E2-9543-B027517549F4

P304

Q27674784-712B058C-E44A-4FB0-B78E-55C17560F378

P31

Q27674784-5301A9D9-E749-42A3-98C3-E01C47CA696A

P3181

Q27674784-D8C739F4-D3C4-4A45-A866-75A4011003E5

P356

Q27674784-CACCB0E0-798C-4F28-852C-597973953C68

P407

Q27674784-92F97EF1-F255-4B72-AB54-BD1C26CE85FC

P433

Q27674784-59A4DEA6-F92D-4CCC-B9B8-07F8AE589928

P478

Q27674784-443B1B9D-4CF2-4D90-B26F-8C58012C1C64

P577

Q27674784-77AFC397-60C1-4084-8EC0-143334A427BB

P5875

Q27674784-F2D62D42-AE9C-4699-AAF2-B4879586DB6B

P698

Q27674784-98B559F9-E6B1-406C-8990-0012B5026D3E

P3181

P356

P1433

Journal of Medicinal Chemistry

P1476

Discovery of a potent, selecti ...... 0) for the treatment of cancer

@en

P2093

Adrian Folks

http://www.w3.org/2001/XMLSchema#string

Alan Olivero

http://www.w3.org/2001/XMLSchema#string

Bing-Yan Zhu

http://www.w3.org/2001/XMLSchema#string

Binqing Wei

http://www.w3.org/2001/XMLSchema#string

Christian Wiesmann

http://www.w3.org/2001/XMLSchema#string

Cristina Lewis

http://www.w3.org/2001/XMLSchema#string

Daniel P Sutherlin

http://www.w3.org/2001/XMLSchema#string

Deepak Sampath

http://www.w3.org/2001/XMLSchema#string

Georgette Castanedo

http://www.w3.org/2001/XMLSchema#string

Irina Chuckowree

http://www.w3.org/2001/XMLSchema#string

P304

7579-87

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3235006

http://www.w3.org/2001/XMLSchema#string

P356

10.1021/JM2009327

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51701312

http://www.w3.org/2001/XMLSchema#string

P698

21981714

http://www.w3.org/2001/XMLSchema#string